Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497 is registered in ClinicalTrials.gov with Zumutor Biologics Inc. as lead sponsor.

NCT NCT06451497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06451497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors
Lead sponsor
Zumutor Biologics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 22, 2024
Completion date
April 30, 2027
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, colorectal cancer, diffuse large b cell lymphoma, head and neck squamous cell carcinoma, high grade ovarian serous adenocarcinoma, non small cell lung cancer, pancreas adenocarcinoma, prostate cancer, renal cell cancer metastatic, triple negative breast cancer, urothelial carcinoma